Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.45 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.45 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.45 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.45 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675895 | 0.97 | LMNA (0.46) | LMNACHRM2CHRM4CHRM1TSHR | |
| Hydrochloric Acid SCHEMBL4199984 | 0.95 | LMNA (0.48) | LMNACHRM2CHRM4CHRM1TSHR | |
| Water SCHEMBL16320706 | 0.95 | LMNA (0.45) | LMNACHRM2CHRM4CHRM1TSHR | |
| Hydrochloric Acid SCHEMBL7631402 | 0.95 | LMNA (0.45) | LMNACHRM2CHRM4CHRM1TSHR | |
| SCHEMBL52510 | 0.74 | MAPT (0.46) | LMNACHRM2CHRM4CHRM1TSHR | |
| Bromide SCHEMBL21643593 | 0.73 | MAPT (0.41) | LMNACHRM2CHRM4CHRM1TSHR | |
| SCHEMBL10529054 | 0.73 | MAPT (0.41) | LMNACHRM2CHRM4CHRM1TSHR | |
| SCHEMBL5582502 | 0.72 | MAPT (0.44) | LMNACHRM2CHRM4CHRM1TSHR | |
| Hydrochloric Acid SCHEMBL9486928 | 0.72 | MAPT (0.50) | LMNACHRM2CHRM4CHRM1TSHR | |
| SCHEMBL27896693 | 0.72 | LMNA (0.52) | LMNACHRM2CHRM4CHRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8628759-B2 | Soft anticholinergic esters | BODOR LABORATORIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8568699-B2 | Soft anticholinergic zwitterions | BODOR LABORATORIES, INC. | 2013-10-29 | — | — | US | disclosed |
| US-20120177590-A1 | SOFT ANTICHOLINERGIC ESTERS | BODOR LABORATORIES, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120141401-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR LABORATORIES, INC. | 2012-06-07 | — | — | US | disclosed |
| US-8071639-B2 | Soft anticholinergic zwitterions | BODOR LABORATORIES, INC. | 2011-12-06 | — | — | US | disclosed |
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | BODOR LABORATORIES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090257969-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR LABORATORIES, INC. | 2009-10-15 | — | — | US | disclosed |
| US-7576210-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-08-18 | — | — | US | disclosed |
| US-7538219-B2 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2009-05-26 | — | — | US | disclosed |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | BODOR LABORATORIES, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080242651-A1 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-10-02 | — | — | US | disclosed |
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | disclosed |
| EP-1957451-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | Bodor, Nicholas S. (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1948596-A2 | SOFT ANTICHOLINERGIC ESTERS | Bodor, Nicholas S. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7399861-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2008-07-15 | — | — | US | disclosed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007058971-A2 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059021-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263341-A1 | SOFT ANTICHOLINERGIC ESTERS | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM4 4/4885CHRM1 2/4885 |
| US-20120177590-A1 | SOFT ANTICHOLINERGIC ESTERS | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM4 4/4885CHRM1 2/4885 |
| US-20120141401-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM4 5/4885CHRM1 2/4885 |
| US-20090257969-A1 | SOFT ANTICHOLINERGIC ZWITTERIONS | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM4 5/4885CHRM1 2/4885 |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, ADRB2, ADRB1 | CHRM2 1/4885CHRM4 20/4885CHRM1 4/4885 |
| US-20080242651-A1 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM4 16/4885CHRM1 2/4885 |
| US-20090075954-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives; 6 beta ,7 beta -epoxy-3 beta -hydroxy-8-ethoxycarbonylmethyl-8-methyl-1 alpha H,5 alpha H-tropanium bromide, di-2-thienylglycolate | CHRNE, CHRM1, ADRB1 | CHRM2 7/4885CHRM4 30/4885CHRM1 2/4885 |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | CHRM2, ADRB1, ADRB2 | CHRM2 1/4885CHRM4 24/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.